{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:46:23Z","timestamp":1765295183651,"version":"3.40.5"},"reference-count":72,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>The scenario of systemic therapy for prostate cancer is rapidly evolving, with new drugs\nand new treatment options. To update the background knowledge of shared uro-oncologic practice,\nwe reviewed current statements and landmarks in systemic therapy. A number of new agents are under\ninvestigation in non-metastatic and metastatic disease. Similarly, new target imaging technologies\nare under development to improve the detection rate of true non-metastatic and true metastatic\npatient. Five new drugs have shown to be effective on progression-free and overall survival in metastat\u00ecc\nprostate cancer. However, the optimal sequencing of these treatments requires further investigation.\nThe tolerability and side effects of the new drugs are also crucial issues to be discussed,\nas well as their activity against the disease. The uro-oncologic team has to stay updated\nabout new medical therapies in order to be confident in debating with other professionals involved\nin prostate cancer decision making. Different points of view and nuances should be shared during\nmultidisciplinary group discussions to achieve a balanced decision in disease management.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009620666201021163919","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T06:22:20Z","timestamp":1603347740000},"page":"107-116","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7495-2424","authenticated-orcid":true,"given":"Fabio","family":"Campodonico","sequence":"first","affiliation":[{"name":"Department of Abdominal Surgery, Urology, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ennas","sequence":"additional","affiliation":[{"name":"Department of Abdominal Surgery, Urology, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Zanardi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterini","family":"Zigoura","sequence":"additional","affiliation":[{"name":"Geriatrics Unit, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6779-1471","authenticated-orcid":true,"given":"Arnoldo","family":"Piccardo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3476-6875","authenticated-orcid":true,"given":"Luca","family":"Foppiani","sequence":"additional","affiliation":[{"name":"Internal Medicine Unit, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Schiavone","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lino","family":"Squillace","sequence":"additional","affiliation":[{"name":"Information Technology, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2635-4491","authenticated-orcid":true,"given":"Andrea","family":"Benelli","sequence":"additional","affiliation":[{"name":"Department of Abdominal Surgery, Urology, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"De Censi","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0092-6332","authenticated-orcid":true,"given":"Filippo","family":"Grillo-Ruggieri","sequence":"additional","affiliation":[{"name":"Radiotherapy Unit, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Introini","sequence":"additional","affiliation":[{"name":"Department of Abdominal Surgery, Urology, Galliera Hospital, Genova,Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"journal-title":"I numeri del cancro in Italia","year":"2018","key":"ref=1","unstructured":"I numeri del cancro in Italia AIOM-AIRTUM2018"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.euo.2018.04.013","volume":"1","author":"Bandini M.","year":"2018","unstructured":"Bandini M.; Mazzone E.; Preisser F.; Nazzani S.; Zaffuto E.; Marchioni M.; Tian Z.; Pompe R.S.; Tilki D.; Graefen M.; Shariat S.F.; Montorsi F.; Saad F.; Briganti A.; Karakiewicz P.; Increase in the annual rate of newly diagnosed metastatic prostate cancer: a contemporary analysis of the Surveillance, Epidemiology and End Results Database. Eur Urol Oncol 2018,1(4),314-320","journal-title":"Eur Urol Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","volume":"43","year":"1941","unstructured":"Huggins.; C, Stevens, R.E. Jr.; Hodges, C.V. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941,43,209-223","journal-title":"Arch Surg"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0022-5347(02)80307-X","volume":"167","author":"Huggins C.","year":"2002","unstructured":"Huggins C.; Hodges C.V.; Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002,167(2 Pt 2),948-951","journal-title":"J Urol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.eururo.2011.08.026","volume":"61","author":"Pagliarulo V.","year":"2012","unstructured":"Pagliarulo V.; Bracarda S.; Eisenberger M.A.; Mottet N.; Schr&#xF6;der F.H.; Sternberg C.N.; Studer U.E.; Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012,61(1),11-25","journal-title":"Eur Urol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","volume":"17","author":"Mohler J.L.","year":"2019","unstructured":"Mohler J.L.; Antonarakis E.S.; Armstrong A.J.; D\u2019Amico A.V.; Davis B.J.; Dorff T.; Eastham J.A.; Enke C.A.; Farrington T.A.; Higano C.S.; Horwitz E.M.; Hurwitz M.; Ippolito J.E.; Kane C.J.; Kuettel M.R.; Lang J.M.; McKenney J.; Netto G.; Penson D.F.; Plimack E.R.; Pow-Sang J.M.; Pugh T.J.; Richey S.; Roach M.; Rosenfeld S.; Schaeffer E.; Shabsigh A.; Small E.J.; Spratt D.E.; Srinivas S.; Tward J.; Shead D.A.; Freedman- Cass D.A.; Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019,17(5),479-505","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.urology.2018.01.010","volume":"116","author":"Cancian M.","year":"2018","unstructured":"Cancian M.; Renzulli J.F.; 2nd. Non metastatic castration-resistant prostate cancer: a modern perspective. Urology 2018,116,13-16","journal-title":"Urology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","volume":"355","year":"2000","unstructured":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists\u2019 Collaborative Group. Lancet 2000,355(9214),1491-1498","journal-title":"Lancet"},{"key":"ref=9","first-page":"CD001526","author":"Schmitt B.","year":"2000","unstructured":"Schmitt B.; Bennett C.; Seidenfeld J.; Samson D.; Wilt T.; Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000(2),CD001526","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"Montgomery R.B.","year":"2008","unstructured":"Montgomery R.B.; Mostaghel E.A.; Vessella R.; Hess D.L.; Kalhorn T.F.; Higano C.S.; True L.D.; Nelson P.S.; Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008,68(11),4447-4454","journal-title":"Cancer Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","volume":"17","author":"Duchesne G.M.","year":"2016","unstructured":"Duchesne G.M.; Woo H.H.; Bassett J.K.; Bowe S.J.; D\u2019Este C.; Frydenberg M.; King M.; Ledwich L.; Loblaw A.; Malone S.; Millar J.; Milne R.; Smith R.G.; Spry N.; Stockler M.; Syme R.A.; Tai K.H.; Turner S.; Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016,17(6),727-737","journal-title":"Lancet Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"Levine G.N.","year":"2010","unstructured":"Levine G.N.; D\u2019Amico A.V.; Berger P.; Clark P.E.; Eckel R.H.; Keating N.L.; Milani R.V.; Sagalowsky A.I.; Smith M.R.; Zakai N.; Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association2010,121(6),833-840","journal-title":"Circulation"},{"key":"ref=13","first-page":"630-642","volume":"66","author":"Mottet N.","year":"2017","unstructured":"Mottet N.; van den Bergh R.C.N.; Briers E.; Bourke L.; Cornford P.; De Santis M.; Gillessen S.; Govorov A.; Grummet J.; Henry A.M.; Lam T.B.; Mason M.D.; van der Poel H.G.; van der Kwast T.H.; Rouvi&#xE8;re O.; Wiegel T.; EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 6: Treatment. Management of PSA-only recurrence after treatment with curative intent. Eur Urol 2017,66,630-642","journal-title":"Eur Urol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ijrobp.2017.02.019","volume":"98","author":"Gay H.A.","year":"2017","unstructured":"Gay H.A.; Sanda M.G.; Liu J.; Wu N.; Hamstra D.A.; Wei J.T.; Dunn R.L.; Klein E.A.; Sandler H.M.; Saigal C.S.; Litwin M.S.; Kuban D.A.; Hembroff L.; Regan M.M.; Chang P.; Michalski J.M.; External beam radiation therapy or brachyteraphy with or without short-course neoadjuvant androgen deprivation therapy: Results of a multicenter, prospective study of quality of life. Int J Radiat Oncol Biol Phys Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium2017,98(2),304-317","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"Nguyen P.L.","year":"2015","unstructured":"Nguyen P.L.; Alibhai S.M.; Basaria S.; D\u2019Amico A.V.; Kantoff P.W.; Keating N.L.; Penson D.F.; Rosario D.J.; Tombal B.; Smith M.R.; Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015,67(5),825-836","journal-title":"Eur Urol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1056\/NEJMoa1201546","volume":"367","author":"Crook J.M.","year":"2012","unstructured":"Crook J.M.; O\u2019Callaghan C.J.; Duncan G.; Dearnaley D.P.; Higano C.S.; Horwitz E.M.; Frymire E.; Malone S.; Chin J.; Nabid A.; Warde P.; Corbett T.; Angyalfi S.; Goldenberg S.L.; Gospodarowicz M.K.; Saad F.; Logue J.P.; Hall E.; Schellhammer P.F.; Ding K.; Klotz L.; Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012,367(10),895-903","journal-title":"N Engl J Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"Hussain M.","year":"2013","unstructured":"Hussain M.; Tangen C.M.; Berry D.L.; Higano C.S.; Crawford E.D.; Liu G.; Wilding G.; Prescott S.; Kanaga Sundaram S.; Small, E.J.; Dawson, N.A.; Donnelly, B.J, Venner, P.M, Vaishampayan, UN, Schellhammer, P.F.; Quinn, D.I.; Raghavan, D.; Ely, B.; Moinpour, C.M.; Vogelzang, N.J.; Thompson, I.M. Jr. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013,368,1314-1325","journal-title":"N Engl J Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1200\/JCO.2012.46.5492","volume":"31","author":"Niraula S.","year":"2013","unstructured":"Niraula S.; Le L.W.; Tannock I.F.; Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013,31(16),2029-2036","journal-title":"J Clin Oncol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1200\/JCO.2015.62.8065","volume":"34","author":"Hussain M.","year":"2016","unstructured":"Hussain M.; Tangen C.; Higano C.; Vogelzang N.; Thompson I.; Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details. J Clin Oncol 2016,34(3),280-285","journal-title":"J Clin Oncol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00345-013-1206-0","volume":"32","author":"Verhagen P.C.M.S.","year":"2014","unstructured":"Verhagen P.C.M.S.; Wildhagen M.F.; Verkerk A.M.; Vjaters E.; Pagi H.; Kukk L.; Bratus D.; Fiala R.; Bangma C.H.; Schr&#xF6;der F.H.; Mickisch G.H.; Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial. World J Urol 2014,32(5),1287-1294","journal-title":"World J Urol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.eururo.2013.03.055","volume":"66","author":"Calais da Silva F.","year":"2014","unstructured":"Calais da Silva F.; Calais da Silva F.M.; Gon&#xE7;alves F.; Santos A.; Kliment J.; Whelan P.; Oliver T.; Antoniou N.; Pastidis S.; Marques Queimadelos A.; Robertson C.; Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol 2014,66(2),232-239","journal-title":"Eur Urol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.eururo.2013.06.034","volume":"65","author":"Sciarra A.","year":"2014","unstructured":"Sciarra A.; Salciccia S.; A novel therapeutic option for castration-resistant prostate cancer: After or before chemotherapy? Eur Urol 2014,65(5),905-906","journal-title":"Eur Urol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"CD006019","DOI":"10.1002\/14651858.CD006019.pub2","author":"Kumar S.","year":"2006","unstructured":"Kumar S.; Shelley M.; Harrison C.; Coles B.; Wilt T.J.; Mason M.D.; Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006(4),CD006019","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","volume":"11","author":"Bolla M.","year":"2010","unstructured":"Bolla M.; Van Tienhoven G.; Warde P.; Dubois J.B.; Mirimanoff R.O.; Storme G.; Bernier J.; Kuten A.; Sternberg C.; Billiet I.; Torecilla J.L.; Pfeffer R.; Cutajar C.L.; Van der Kwast T.; Collette L.; External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010,11(11),1066-1073","journal-title":"Lancet Oncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.2007.13.9881","volume":"26","author":"Roach M.","year":"2008","unstructured":"Roach M.; Bae K.; Speight J.; Wolkov H.B.; Rubin P.; Lee R.J.; Lawton C.; Valicenti R.; Grignon D.; Pilepich M.; Short-term neoadjuvant androgen deprivation therapy and external-beam radiation radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008,26,255-591","journal-title":"J Clin Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","volume":"69","author":"Lawton C.A.","year":"2007","unstructured":"Lawton C.A.; DeSilvio M.; Roach M.; Uhl V.; Kirsch R.; Seider M.; Rotman M.; Jones C.; Asbell S.; Valicenti R.; Hahn S.; Thomas C.R.; An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions. Int J Radiat Oncol Biol Phys 2007,69(3),646-655","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=27","first-page":"14","volume":"11","author":"Paller C.J.","year":"2013","unstructured":"Paller C.J.; Antonarakis E.S.; Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions. Clin Adv Hematol Oncol 2013,11(1),14-23","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"Roach M.","year":"2006","unstructured":"Roach M.; Hanks G.; Thames H.; Schellhammer P.; Shipley W.U.; Sokol G.H.; Sandler H.; Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006,65(4),965-974","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0090-4295(94)90180-5","volume":"43","author":"Partin A.W.","year":"1994","unstructured":"Partin A.W.; Pearson J.D.; Landis P.K.; Carter H.B.; Pound C.R.; Clemens J.Q.; Epstein J.I.; Walsh P.C.; Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994,43(5),649-659","journal-title":"Urology"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","volume":"43","author":"Shen G.","year":"2014","unstructured":"Shen G.; Deng H.; Hu S.; Jia Z.; Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 2014,43(11),1503-1513","journal-title":"Skeletal Radiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"H&#xF6;vels A.M.","year":"2008","unstructured":"H&#xF6;vels A.M.; Heesakkers R.A.; Adang E.M.; Jager G.J.; Strum S.; Hoogeveen Y.L.; Severens J.L.; Barentsz J.O.; The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008,63(4),387-395","journal-title":"Clin Radiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00345-015-1669-2","volume":"34","author":"Gabriele D.","year":"2016","unstructured":"Gabriele D.; Collura D.; Oderda M.; Stura I.; Fiorito C.; Porpiglia F.; Terrone C.; Zacchero M.; Guiot C.; Gabriele P.; Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database. World J Urol 2016,34(4),517-523","journal-title":"World J Urol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urology.2016.02.014","volume":"96","author":"Kiss B.","year":"2016","unstructured":"Kiss B.; Thoeny H.C.; Studer U.E.; Current status of limph node imaging in bladder and prostate cancer. Urology 2016,96,1-7","journal-title":"Urology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.urolonc.2016.01.004","volume":"34","author":"Panebianco V.","year":"2016","unstructured":"Panebianco V.; Barchetti F.; Grompone M.D.; Colarieti A.; Salvo V.; Cardone G.; Catalano C.; Magnetic resonance imaging for localization of prostate cancer in the setting of biochemical recurrence. Urol Oncol 2016,34(7),303-310","journal-title":"Urol Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000493169","volume":"102","author":"Kim S.J.","year":"2019","unstructured":"Kim S.J.; Lee S.W.; Ha H.K.; Diagnostic performance of radiolabeled prostate-specific membrane antigen positron emission tomography\/computed tomography for primary lymph node staging in newly diagnosed intermediate to high-risk prostate cancer patients: a systematic review and meta-analysis. Urol Int 2019,102(1),27-36","journal-title":"Urol Int"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/j.ejrad.2012.04.027","volume":"81","author":"Fuccio C.","year":"2012","unstructured":"Fuccio C.; Castellucci P.; Schiavina R.; Guidalotti P.L.; Gavaruzzi G.; Montini G.C.; Nanni C.; Marzola M.C.; Rubello D.; Fanti S.; Role of 11C-choline PET\/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol 2012,81(8),e893-e896","journal-title":"Eur J Radiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1515\/cclm-2013-0675","volume":"52","author":"Treglia G.","year":"2014","unstructured":"Treglia G.; Ceriani L.; Sadeghi R.; Giovacchini G.; Giovanella L.; Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET\/CT in restaging prostate cancer patients: a meta-analysis. Clin Chem Lab Med 2014,52(5),725-733","journal-title":"Clin Chem Lab Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-007-0530-2","volume":"35","author":"Reske S.N.","year":"2008","unstructured":"Reske S.N.; Blumstein N.M.; Glatting G.; [11C]choline PET\/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008,35(1),9-17","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00259-016-3329-1","volume":"43","author":"Nanni C.","year":"2016","unstructured":"Nanni C.; Zanoni L.; Pultrone C.; Schiavina R.; Brunocilla E.; Lodi F.; Malizia C.; Ferrari M.; Rigatti P.; Fonti C.; Martorana G.; Fanti S.; (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET\/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging 2016,43(9),1601-1610","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","volume":"4","author":"von Eyben F.E.","year":"2018","unstructured":"von Eyben F.E.; Picchio M.; von Eyben R.; Rhee H.; Bauman G.; 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 2018,4(5),686-693","journal-title":"Eur Urol Focus"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2967\/jnumed.117.195628","volume":"59","author":"Piccardo A.","year":"2018","unstructured":"Piccardo A.; Paparo F.; Puntoni M.; Righi S.; Bottoni G.; Bacigalupo L.; Zanardi S.; DeCensi A.; Ferrarazzo G.; Gambaro M.; Ruggieri F.G.; Campodonico F.; Tomasello L.; Timossi L.; Sola S.; Lopci E.; Cabria M.; \nCuClPET\/CT in prostate cancer relapse. J Nucl Med 2018,59(3),444-451","journal-title":"J Nucl Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"Scher H.I.","year":"2016","unstructured":"Scher H.I.; Morris M.J.; Stadler W.M.; Higano C.; Basch E.; Fizazi K.; Antonarakis E.S.; Beer T.M.; Carducci M.A.; Chi K.N.; Corn P.G.; de Bono J.S.; Dreicer R.; George D.J.; Heath E.I.; Hussain M.; Kelly W.K.; Liu G.; Logothetis C.; Nanus D.; Stein M.N.; Rathkopf D.E.; Slovin S.F.; Ryan C.J.; Sartor O.; Small E.J.; Smith M.R.; Sternberg C.N.; Taplin M.E.; Wilding G.; Nelson P.S.; Schwartz L.H.; Halabi S.; Kantoff P.W.; Armstrong A.J.; Trial design and objectives for castration resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group3. J Clin Oncol Prostate Cancer Clinical Trials Working Group 32016,34(12),1402-1418","journal-title":"J Clin Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","volume":"23","author":"Smith M.R.","year":"2005","unstructured":"Smith M.R.; Kabbinavar F.; Saad F.; Hussain A.; Gittelman M.C.; Bilhartz D.L.; Wynne C.; Murray R.; Zinner N.R.; Schulman C.; Linnartz R.; Zheng M.; Goessl C.; Hei Y.J.; Small E.J.; Cook R.; Higano C.S.; Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005,23(13),2918-2925","journal-title":"J Clin Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"Smith M.R.","year":"2018","unstructured":"Smith M.R.; Saad F.; Chowdhury S.; Oudard S.; Hadaschik B.A.; Graff J.N.; Olmos D.; Mainwaring P.N.; Lee J.Y.; Uemura H.; Lopez-Gitlitz A.; Trudel G.C.; Espina B.M.; Shu Y.; Park Y.C.; Rackoff W.R.; Yu M.K.; Small E.J.; SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med SPARTAN Investigators2018,378(15),1408-1418","journal-title":"N Engl J Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"Penson D.F.","year":"2016","unstructured":"Penson D.F.; Armstrong A.J.; Concepcion R.; Agarwal N.; Olsson C.; Karsh L.; Dunshee C.; Wang F.; Wu K.; Krivoshik A.; Phung D.; Higano C.S.; Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol 2016,34(18),2098-2106","journal-title":"J Clin Oncol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"Sternberg C.N.","year":"2020","unstructured":"Sternberg C.N.; Fizazi K.; Saad F.; Shore N.D.; De Giorgi U.; Penson D.F.; Ferreira U.; Efstathiou E.; Madziarska K.; Kolinsky M.P.; Cubero D.I.G.; Noerby B.; Zohren F.; Lin X.; Modelska K.; Sugg J.; Steinberg J.; Hussain M.; Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med PROSPER Investigators2020,382(23),2197-2206","journal-title":"N Engl J Med"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","volume":"65","author":"Heidenreich A.","year":"2014","unstructured":"Heidenreich A.; Bastian P.J.; Bellmunt J.; Bolla M.; Joniau S.; van der Kwast T.; Mason M.; Matveev V.; Wiegel T.; Zattoni F.; Mottet N.; EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol European Association of Urology2014,65(2),467-479","journal-title":"Eur Urol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","volume":"28","author":"Franke R.M.","year":"2010","unstructured":"Franke R.M.; Carducci M.A.; Rudek M.A.; Baker S.D.; Sparreboom A.; Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 2010,28(30),4562-4567","journal-title":"J Clin Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"Tannock I.F.","year":"2004","unstructured":"Tannock I.F.; de Wit R.; Berry W.R.; Horti J.; Pluzanska A.; Chi K.N.; Oudard S.; Th&#xE9;odore C.; James N.D.; Turesson I.; Rosenthal M.A.; Eisenberger M.A.; Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med TAX 327 Investigators2004,351(15),1502-1512","journal-title":"N Engl J Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"Attard G.","year":"2008","unstructured":"Attard G.; Reid A.H.; Yap T.A.; Raynaud F.; Dowsett M.; Settatree S.; Barrett M.; Parker C.; Martins V.; Folkerd E.; Clark J.; Cooper C.S.; Kaye S.B.; Dearnaley D.; Lee G.; de Bono J.S.; Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008,26(28),4563-4571","journal-title":"J Clin Oncol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"de Bono J.S.","year":"2011","unstructured":"de Bono J.S.; Logothetis C.J.; Molina A.; Fizazi K.; North S.; Chu L.; Chi K.N.; Jones R.J.; Goodman O.B.; Saad F.; Staffurth J.N.; Mainwaring P.; Harland S.; Flaig T.W.; Hutson T.E.; Cheng T.; Patterson H.; Hainsworth J.D.; Ryan C.J.; Sternberg C.N.; Ellard S.L.; Fl&#xE9;chon A.; Saleh M.; Scholz M.; Efstathiou E.; Zivi A.; Bianchini D.; Loriot Y.; Chieffo N.; Kheoh T.; Haqq C.M.; Scher H.I.; Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med COU-AA-301 Investigators2011,364(21),1995-2005","journal-title":"N Engl J Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"Ryan C.J.","year":"2013","unstructured":"Ryan C.J.; Smith M.R.; de Bono J.S.; Molina A.; Logothetis C.J.; de Souza P.; Fizazi K.; Mainwaring P.; Piulats J.M.; Ng S.; Carles J.; Mulders P.F.; Basch E.; Small E.J.; Saad F.; Schrijvers D.; Van Poppel H.; Mukherjee S.D.; Suttmann H.; Gerritsen W.R.; Flaig T.W.; George D.J.; Yu E.Y.; Efstathiou E.; Pantuck A.; Winquist E.; Higano C.S.; Taplin M.E.; Park Y.; Kheoh T.; Griffin T.; Scher H.I.; Rathkopf D.E.; Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med COU-AA-302 Investigators2013,368(2),138-148","journal-title":"N Engl J Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"Tran C.","year":"2009","unstructured":"Tran C.; Ouk S.; Clegg N.J.; Chen Y.; Watson P.A.; Arora V.; Wongvipat J.; Smith-Jones P.M.; Yoo D.; Kwon A.; Wasielewska T.; Welsbie D.; Chen C.D.; Higano C.S.; Beer T.M.; Hung D.T.; Scher H.I.; Jung M.E.; Sawyers C.L.; Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009,324(5928),787-790","journal-title":"Science"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"Scher H.I.","year":"2012","unstructured":"Scher H.I.; Fizazi K.; Saad F.; Taplin M.E.; Sternberg C.N.; Miller K.; de Wit R.; Mulders P.; Chi K.N.; Shore N.D.; Armstrong A.J.; Flaig T.W.; Fl&#xE9;chon A.; Mainwaring P.; Fleming M.; Hainsworth J.D.; Hirmand M.; Selby B.; Seely L.; de Bono J.S.; Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med AFFIRM Investigators2012,367(13),1187-1197","journal-title":"N Engl J Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"Beer T.M.","year":"2014","unstructured":"Beer T.M.; Armstrong A.J.; Rathkopf D.E.; Loriot Y.; Sternberg C.N.; Higano C.S.; Iversen P.; Bhattacharya S.; Carles J.; Chowdhury S.; Davis I.D.; de Bono J.S.; Evans C.P.; Fizazi K.; Joshua A.M.; Kim C.S.; Kimura G.; Mainwaring P.; Mansbach H.; Miller K.; Noonberg S.B.; Perabo F.; Phung D.; Saad F.; Scher H.I.; Taplin M.E.; Venner P.M.; Tombal B.; Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med PREVAIL Investigators2014,371(5),424-433","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"de Bono J.S.","year":"2010","unstructured":"de Bono J.S.; Outard S.; Ozguroglu M.; Hansen S.; Machiels J.P.; Kocak I.; Gravis G.; Bodrogi I.; Mackenzie M.J.; Shen L.; Roessner M.; Gupta S.; Sartor A.O.; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010,376,1147-1154","journal-title":"Lancet"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"Parker C.","year":"2013","unstructured":"Parker C.; Nilsson S.; Heinrich D.; Helle S.I.; O\u2019Sullivan J.M.; Foss&#xE5; S.D.; Chodacki A.; Wiechno P.; Logue J.; Seke M.; Widmark A.; Johannessen D.C.; Hoskin P.; Bottomley D.; James N.D.; Solberg A.; Syndikus I.; Kliment J.; Wedel S.; Boehmer S.; Dall\u2019Oglio M.; Franz&#xE9;n L.; Coleman R.; Vogelzang N.J.; O\u2019Bryan-Tear C.G.; Staudacher K.; Garcia-Vargas J.; Shan M.; Bruland &#xD8;.S.; Sartor O.; Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med ALSYMPCA Investigators2013,369(3),213-223","journal-title":"N Engl J Med"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2174\/1568009617666171122145852","volume":"18","author":"Salvi S.","year":"2018","unstructured":"Salvi S.; Conteduca V.; Lolli C.; Testoni S.; Casadio V.; Zaccheroni A.; Rossi L.; Burgio S.L.; Menna C.; Schepisi G.; De Giorgi U.; AR copy number and AR signaling-directed therapies in castrationresistant prostate cancer. Curr Cancer Drug Targets 2018,18(9),869-876","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","volume":"381","author":"de Wit R.","year":"2019","unstructured":"de Wit R.; de Bono J.; Sternberg C.N.; Fizazi K.; Tombal B.; W&#xFC;lfing C.; Kramer G.; Eymard J.C.; Bamias A.; Carles J.; Iacovelli R.; Melichar B.; Sverrisd&#xF3;ttir &#xC1;.; Theodore C.; Feyerabend S.; Helissey C.; Ozatilgan A.; Geffriaud-Ricouard C.; Castellano D.; cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med CARD investigators2019,381(26),2506-2518","journal-title":"N Engl J Med"},{"year":"2019","key":"ref=60","unstructured":"AIOM Linee guida Carcinoma della Prostata. Edizione 2019 https:\/\/www.aiom.it\/linee-guida-aiom-carcinoma-della-prostata-2019\/"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000502655","volume":"103","author":"Miyoshi Y.","year":"2019","unstructured":"Miyoshi Y.; Sakamoto S.; Kawahara T.; Uemura K.; Yokomizo Y.; Uemura H.; Correlation between automated bone scan index change after cabazitaxel and survival among men with castration-resistant prostate cancer. Urol Int 2019,103(3),279-284","journal-title":"Urol Int"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"Sweeney C.J.","year":"2015","unstructured":"Sweeney C.J.; Chen Y.H.; Carducci M.; Liu G.; Jarrard D.F.; Eisenberger M.; Wong Y.N.; Hahn N.; Kohli M.; Cooney M.M.; Dreicer R.; Vogelzang N.J.; Picus J.; Shevrin D.; Hussain M.; Garcia J.A.; DiPaola R.S.; Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015,373(8),737-746","journal-title":"N Engl J Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"James N.D.","year":"2016","unstructured":"James N.D.; Sydes M.R.; Clarke N.W.; Mason M.D.; Dearnaley D.P.; Spears M.R.; Ritchie A.W.; Parker C.C.; Russell J.M.; Attard G.; de Bono J.; Cross W.; Jones R.J.; Thalmann G.; Amos C.; Matheson D.; Millman R.; Alzouebi M.; Beesley S.; Birtle A.J.; Brock S.; Cathomas R.; Chakraborti P.; Chowdhury S.; Cook A.; Elliott T.; Gale J.; Gibbs S.; Graham J.D.; Hetherington J.; Hughes R.; Laing R.; McKinna F.; McLaren D.B.; O\u2019Sullivan J.M.; Parikh O.; Peedell C.; Protheroe A.; Robinson A.J.; Srihari N.; Srinivasan R.; Staffurth J.; Sundar S.; Tolan S.; Tsang D.; Wagstaff J.; Parmar M.K.; Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet STAMPEDE investigators2016,387(10024),1163-1177","journal-title":"Lancet"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"James N.D.","year":"2017","unstructured":"James N.D.; de Bono J.S.; Spears M.R.; Clarke N.W.; Mason M.D.; Dearnaley D.P.; Ritchie A.W.S.; Amos C.L.; Gilson C.; Jones R.J.; Matheson D.; Millman R.; Attard G.; Chowdhury S.; Cross W.R.; Gillessen S.; Parker C.C.; Russell J.M.; Berthold D.R.; Brawley C.; Adab F.; Aung S.; Birtle A.J.; Bowen J.; Brock S.; Chakraborti P.; Ferguson C.; Gale J.; Gray E.; Hingorani M.; Hoskin P.J.; Lester J.F.; Malik Z.I.; McKinna F.; McPhail N.; Money-Kyrle J.; O\u2019Sullivan J.; Parikh O.; Protheroe A.; Robinson A.; Srihari N.N.; Thomas C.; Wagstaff J.; Wylie J.; Zarkar A.; Parmar M.K.B.; Sydes M.R.; Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med STAMPEDE Investigators2017,377(4),338-351","journal-title":"N Engl J Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"Davis I.D.","year":"2019","unstructured":"Davis I.D.; Martin A.J.; Stockler M.R.; Begbie S.; Chi K.N.; Chowdhury S.; Coskinas X.; Frydenberg M.; Hague W.E.; Horvath L.G.; Joshua A.M.; Lawrence N.J.; Marx G.; McCaffrey J.; McDermott R.; McJannett M.; North S.A.; Parnis F.; Parulekar W.; Pook D.W.; Reaume M.N.; Sandhu S.K.; Tan A.; Tan T.H.; Thomson A.; Tu E.; Vera-Badillo F.; Williams S.G.; Yip S.; Zhang A.Y.; Zielinski R.R.; Sweeney C.J.; Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group2019,381(2),121-131","journal-title":"N Engl J Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","volume":"379","author":"Smith M.R.","year":"2012","unstructured":"Smith M.R.; Saad F.; Coleman R.; Shore N.; Fizazi K.; Tombal B.; Miller K.; Sieber P.; Karsh L.; Dami&#xE3;o R.; Tammela T.L.; Egerdie B.; Van Poppel H.; Chin J.; Morote J.; G&#xF3;mez-Veiga F.; Borkowski T.; Ye Z.; Kupic A.; Dansey R.; Goessl C.; Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012,379(9810),39-46","journal-title":"Lancet"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21681805.2019.1570328","volume":"53","author":"Poulsen M.H.","year":"2019","unstructured":"Poulsen M.H.; Frost M.; Abrahamsen B.; Gerke O.; Walter S.; Lund L.; Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. Scand J Urol 2019,53(1),34-39","journal-title":"Scand J Urol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/pcan.2016.25","volume":"19","author":"Kiwata J.L.","year":"2016","unstructured":"Kiwata J.L.; Dorff T.B.; Schroeder E.T.; Gross M.E.; Dieli-Conwright C.M.; A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. Prostate Cancer Prostatic Dis 2016,19(4),323-332","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=69","first-page":"115","volume":"16","author":"Tzortzis V.","year":"2017","unstructured":"Tzortzis V.; Samarinas M.; Zachos I.; Oeconomou A.; Pisters L.L.; Bargiota A.; Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications. Hormones (Athens) 2017,16(2),115-123","journal-title":"Hormones (Athens)"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3389\/fendo.2019.00345","volume":"10","author":"Pivonello R.","year":"2019","unstructured":"Pivonello R.; Menafra D.; Riccio E.; Garifalos F.; Mazzella M.; de Angelis C.; Colao A.; Metabolic Disorders and Male Hypogonadotropic Hypogonadism. Front Endocrinol (Lausanne) 2019,10,345","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"Bhatia N.","year":"2016","unstructured":"Bhatia N.; Santos M.; Jones L.W.; Beckman J.A.; Penson D.F.; Morgans A.K.; Moslehi J.; Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer: ABCDE Steps to Reduce Cardiovascular Disease in Patients With Prostate Cancer. Circulation 2016,133(5),537-541","journal-title":"Circulation"},{"key":"ref=72","first-page":"3877","volume":"10","author":"Dai D.","year":"2018","unstructured":"Dai D.; Han S.; Li L.; Guo Y.; Wei Y.; Jin H.; Wang X.; Anemia is associated with poor outcomes of metastatic castration-resistant prostate cancer, a systematic review and meta-analysis. Am J Transl Res 2018,10(12),3877-3886","journal-title":"Am J Transl Res"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187089","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187089\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/187089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T05:29:36Z","timestamp":1649482176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187089\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009620666201021163919","relation":{},"ISSN":["1568-0096"],"issn-type":[{"type":"print","value":"1568-0096"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}